Novel Clinical Trial Designs In Oncology: An Histology-Independent Approach
Cancer’s heterogeneity is a leading reason why product development in this therapeutic area is so risky and costly – and why the pharma industry has not yet addressed all needs in the market. Because low-incidence tumors present recruitment challenges and have lower commercial potential than high-incidence ones, they receive less attention from drug developers; meanwhile, new therapies for high-incidence tumors must demonstrate higher efficacy than therapeutic alternatives in order to differentiate themselves.
You may also be interested in...
The Independent Beauty Association’s Akemi Ooka, head of global supply chain resources, and new board chair Elizabeth Corrigan sat down with HBW Insight to discuss ongoing supply chain challenges, how the trade association’s members are adapting, and prospects for relief ahead.
International Flavors & Fragrances looks for CEO to replace Andreas Fibig; Ultrahuman Healthcare appoints private equity expert as business chief; prebiotics developer Clasado taps nutritional scientist; Abbott kicks off nutritional partnership with Real Madrid; and CRN adjusts membership fees.
Execs told Scrip they hope to get Tyrvaya (varenicline) onto formularies and aim for pricing that would make its nasal spray competitive with Restasis and Xiidra.